Sagetis Biotech is developing an innovative polymeric technology to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors, and is developing SAG-101: a polymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma.
Sagetis Biotech, S.L.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.sagetis-biotech.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
AddressVia Augusta, 394, 08017BarcelonaSpain
Via Augusta, 394, 08017
Barcelona
Spain
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/sagetis-biotech-s-l-” connections=”true” suffix=””]
Sagetis Biotech VIROSHIELD_ coating technology modify the behavior of oncolytic viruses, improving their therapeutic effect by different means. The coated oncolytic adenoviruses are protected against pre-existing neutralizing antibodies, by masking their surface antigenic epitopes, while preserving their transduction capability.
In July 2011, Sagetis Biotech raised $2,000,000 in Series B round from Caixa Capital Risc.